Groupe la Francaise Invests $510,000 in Theravance Biopharma, Inc. $TBPH

Groupe la Francaise bought a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $510,000.

Several other institutional investors and hedge funds have also recently modified their holdings of TBPH. Quarry LP acquired a new position in Theravance Biopharma in the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its holdings in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the period. CIBC Private Wealth Group LLC grew its holdings in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares in the last quarter. Finally, Virtus Advisers LLC purchased a new stake in shares of Theravance Biopharma in the fourth quarter valued at approximately $170,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insider Activity

In other news, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. The trade was a 5.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider owned 9,174,453 shares of the company’s stock, valued at $155,965,701. This trade represents a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TBPH shares. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. JonesTrading lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. BTIG Research cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Finally, HC Wainwright downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, Theravance Biopharma currently has a consensus rating of “Hold” and an average price target of $19.40.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $17.06 on Wednesday. Theravance Biopharma, Inc. has a fifty-two week low of $13.08 and a fifty-two week high of $21.03. The stock’s fifty day moving average is $16.95 and its two-hundred day moving average is $16.49. The firm has a market capitalization of $885.76 million, a P/E ratio of 16.89 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The business had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. On average, equities analysts forecast that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.